Methylphenidate in the Treatment of Cocaine Dependent Patients With Adult Attention Deficit Hyperactivity Disorder - 5
This study has been completed.
Information provided by:
National Institute on Drug Abuse (NIDA)
First received: April 18, 2001
Last updated: October 17, 2012
Last verified: October 2012
The purpose of this study is the use of Methylphenidate in the treatment of cocaine dependence and Attention Deficit Hyperactivity Disorder (ADHD) comorbidity.
Primary Purpose: Treatment
||Methyphendidate in the Treatment of Cocaine Dependent Patients With Adult ADHD
Primary Outcome Measures:
- Cocaine use
- Methylphenidate retention
- Safety assessments
- Psychosocial counseling sessions
| Estimated Enrollment:
| Study Start Date:
The objective of this study is to determine the safety and efficacy of methylphenidate in a population of patients who are cocaine dependent and suffer from attention deficit hyperactivity disorder.
|Ages Eligible for Study:
||21 Years to 50 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Cocaine-dependent. Meets the DSM-IV criteria for ADHD. Actively using cocaine within the past 30 days of screening.
Symptoms of AIDS. Significant medical disorder. DSM-IV criteria for any substance other than cocaine, alcohol, nicotine, marijuana, caffeine. Requires detoxification from ETOH or benzos. History of seizures.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00015223
|Cincinnati, Ohio, United States |
||Gene Somoza, M.D.
||U of Cincinnati
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||April 18, 2001
||October 17, 2012
||United States: Federal Government
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 22, 2014
Attention Deficit Disorder with Hyperactivity
Attention Deficit and Disruptive Behavior Disorders
Mental Disorders Diagnosed in Childhood
Central Nervous System Agents
Central Nervous System Stimulants
Dopamine Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs